Lonza
Walkersville, MD 14 June 2010 – Lonza is pleased to announce the availability of cryopreserved Clonetics® Human Retinal Pigment Epithelial (hRPE) Cells and optimized RtEGM™ Growth Medium BulletKit® for ophthalmologic research including age-related macular degeneration, retinistis pigmentosa, and gene expression profiles of RPE.
Lonza now provides these highly specialized cells with optimized growth medium based on proprietary isolation techniques developed by Lonza Walkersville's Research and Development group. Clonetics® HRPE cells are sold at passage 2 and guaranteed through 5 additional population doublings. Cells are also tested for cell-specific performance in the RtEGM™ Retinal Pigment Epithelial Growth Medium. Performance markers include ≥ 90% positive for pancytokeratin, ≤ 10% positive for fibroblast
contamination, ≥ 90% for tight conjunctions, and ≤ 1% positive for endothelial marker CD31.
The retinal pigment epithelium (RPE) is comprised of hexagonal cells organized into a monolayer that is densely packed with pigment granules. RPE cells play a critical role in visual function and photoreceptor viability.
For more information on this product or to place an order, please visit www.lonzabio.com. For technical service please call 1.800.654.4452 opt 2.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. At the site in Cologne, Lonza develops and commercializes non-viral gene transfer products for primary cells and difficult-to-transfect cell lines. These
cells are important model systems for both basic and clinical research as they more accurately reflect the condition and behavior of cells within an organism when compared to commonly used laboratory cell lines. With the specially developed Amaxa® Nucleofector® Technology, the functionality of different genes can now be analyzed in biologically relevant cell types. These results are used to more efficiently identify new targets for pharmaceuticals and therapies.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
For further Information:
Lonza Group Ltd
Media Relations
Dominik Werner
Phone +41 61 316 8798
[email protected]
Lonza Cologne AG
Marketing Communication
and Product PR
Corinna König-Wildförster
Phone: +49 221 99199 464
[email protected]
Lonza Walkersville, Inc
Product Manager
Research Solutions
Marjorie Smithhisler
Phone: +1 301 898 7025, ext. 2543
[email protected]